SCHEMBL4004912

SCHEMBL4004912

Nc1cnc(Br)cc1Nc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.48
▸ GAA P10253 7/20 0.48
▸ KDM4E B2RXH2 7/20 0.48
▸ ALDH1A1 P00352 6/20 0.48
▸ MEN1 O00255 5/20 0.48
▸ KMT2A Q03164 5/20 0.48
▸ LMNA P02545 3/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ HTT P42858 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ EGFR P00533 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ ALK Q9UM73 2/20 0.42
▸ GFER P55789 3/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19964497 0.85 ALDH1A1 (0.40) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL19243778 0.83 GAA (0.49) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL19964834 0.80 SIRT2 (0.56) MEN1KMT2ATP53ATR
SCHEMBL15286061 0.80 KDM4E (0.47) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL24270834 0.79 GAA (0.50) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL29492714 0.79 GAA (0.50) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL21697451 0.79 EGFR (0.47) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL5084625 0.75 MAPT (0.67) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL3996405 0.73 ALDH1A1 (0.58) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL19851138 0.73 GAA (0.42) MAPTGAAKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547779-B2 Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors GLAXO GROUP LIMITED (GB) 2009-06-16 — — US disclosed
US-20080234261-A1 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234261-A1 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors TNK2, ROCK1, ARHGDIB MAPT 2720/4885GAA 3133/4885KDM4E 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback